RSS

myeloid cell leukaemia 1 (MCL1)

Boehringer Ingelheim and Vanderbilt University have expanded their partnership to develop novel anti-cancer drugs that inhibit the myeloid cell leukaemia 1 (MCL1) protein, which is highly prevalent in many difficult to treat cancers. more

News